| 4.36 0 (0%) | 12-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 5.11 | 1-year : | 5.97 |
| Resists | First : | 4.37 | Second : | 5.11 |
| Pivot price | 4.19 |
|||
| Supports | First : | 4.13 | Second : | 3.99 |
| MAs | MA(5) : | 4.26 |
MA(20) : | 4.22 |
| MA(100) : | 3.71 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 90.7 |
D(3) : | 76.9 |
| RSI | RSI(14): 58.1 | |||
| 52-week | High : | 5.75 | Low : | 1.77 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ADVM ] has closed Bollinger Bands are 67.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 26 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.37 - 4.39 | 4.39 - 4.41 |
| Low: | 4.19 - 4.21 | 4.21 - 4.23 |
| Close: | 4.32 - 4.36 | 4.36 - 4.4 |
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Tue, 09 Dec 2025
Lilly completes tender offer for Adverum Biotechnologies - Investing.com
Tue, 09 Dec 2025
Adverum Biotechnologies Stock (ADVM) Opinions on Lilly Acquisition - Quiver Quantitative
Mon, 08 Dec 2025
Insider Buying: Laurent Fischer Acquires Shares of Adverum Biote - GuruFocus
Wed, 29 Oct 2025
RBC Capital Maintains Adverum Biotechnologies (ADVM) Sector Perform Recommendation - Nasdaq
Mon, 27 Oct 2025
ADVM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Adverum Biotechnologies, Inc. Is Fair to Shareholders - Business Wire
Fri, 24 Oct 2025
Eli Lilly To Acquire Adverum Biotechnologies - Stocktwits
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 22 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 13.2 (%) |
| Held by Institutions | 88.3 (%) |
| Shares Short | 811 (K) |
| Shares Short P.Month | 875 (K) |
| EPS | -8.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.53 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -76.9 % |
| Return on Equity (ttm) | -417.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -3.5 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -8.44 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -138 (M) |
| Levered Free Cash Flow | -78 (M) |
| PE Ratio | -0.51 |
| PEG Ratio | 0 |
| Price to Book value | -1.73 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|